B8F.DE Biofrontera AG XETRA €6.804 intraday jump 28 Jan 2026: watch volume
The B8F.DE stock surged intraday to €6.804 on XETRA on 28 Jan 2026 on heavy volume, marking a sharp re-rating from the open at €0.368 and previous close €0.324. Volume hit 45,797 vs average 605, a relative volume of 75.70x, making Biofrontera AG a top high-volume mover in Germany today. Traders and analysts are watching liquidity and valuation after this volatile move. We examine drivers, key ratios, risks and a model-based forecast to help frame intraday trading and short-term positioning.
Intraday price action and volume: B8F.DE stock snapshot
Trade prints show Biofrontera AG (B8F.DE) ran to a day high of €6.804 from an open of €0.368 and a previous close of €0.324. Volume of 45,797 shares dwarfed the average volume of 605, producing outsized intraday liquidity and price dispersion.
This move pushed the intraday range from a low of €0.296 to the high €6.804, creating stretched short-term technicals and leaving large bid-ask gaps for active traders.
Fundamentals and valuation: what the numbers say about B8F.DE stock
Biofrontera AG reports EPS of -0.21 and a negative trailing PE reported as -32.40, reflecting recent losses. Market capitalization stands at €20,673,478.00, with 3,038,430 shares outstanding and a book value per share of €0.31.
Key valuation multiples include price-to-sales 0.64, price-to-book 21.73, and enterprise value to EBITDA 3.36. The company shows a current ratio of 1.76 and low net debt, but free cash flow per share is negative at -0.04, underlining funding sensitivity for small-cap biopharma players.
Technical context and trading metrics for B8F.DE stock
Short-term momentum metrics are extreme: the 50-day average price €6.53 is near the current level while the 200-day average €9.19 sits higher, indicating medium-term resistance. Year high is €22.58 and year low €0.296, highlighting extreme historical volatility.
Relative volume at 75.70x and average daily volume 605 show today’s move is liquidity-driven. For intraday traders, watch gap fills, VWAP, and stop placement given wide price swings.
Sector drivers, company catalysts and risks for B8F.DE stock
Biofrontera AG operates in Healthcare, specifically Drug Manufacturers – Specialty & Generic. Its dermatology products, including Ameluz and Xepi, and partnerships such as the tie with Maruho, profile the company in a stable niche.
Risks include small market cap, negative EPS, long inventory days (269) and irregular trading patterns. Sector averages show more stable margins and larger caps; Biofrontera’s small size increases event risk and sensitivity to clinical, regulatory or licensing updates.
Meyka AI grade and model outlook for B8F.DE stock
Meyka AI rates B8F.DE with a score out of 100: 58.66 / 100, Grade C+, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational and not financial advice.
Meyka AI’s forecast model projects a 12‑month target of €8.50 versus the current price €6.804, implying an upside of 24.93%. Forecasts are model-based projections and not guarantees. Traders should weigh volatility and the company’s negative EPS when sizing positions.
Trading strategy and liquidity note for B8F.DE stock
High intraday volume creates opportunities for short-term traders but raises execution risk for longer-term investors. Consider using limit orders, smaller position sizes and predefined exit rules given the stock’s rapid moves and low float.
Analyst consensus data is limited. A cautious playbook is to monitor newsflow, confirm sustained volume above the 50‑day average, and treat today’s spike as event-driven until fundamentals and guidance catch up.
Final Thoughts
Key takeaways for B8F.DE stock: intraday prints pushed Biofrontera AG to €6.804 on XETRA with 45,797 shares traded, creating an outsized liquidity event versus an average of 605. Fundamentals remain mixed: negative EPS -0.21, price-to-sales 0.64, and limited market cap €20,673,478.00 increase headline risk. Meyka AI rates B8F.DE at 58.66/100 (C+, HOLD) and flags that the stock is sensitive to news, regulatory items and partner outcomes. Meyka AI’s forecast model projects a €8.50 12‑month price target versus the current €6.804, an implied upside of 24.93%. Forecasts are model-based projections and not guarantees. For traders, this is a high-volatility, high-liquidity intraday situation; for investors, wait for clearer operational or revenue traction before increasing exposure.
FAQs
What caused today’s spike in B8F.DE stock and should I trade it?
Intraday volume and price prints show a jump to €6.804 with 45,797 shares traded. No confirmed company release is required for such moves. Trading is possible but risky; use tight risk controls, small sizes and confirm sustained volume before holding overnight.
What is Meyka AI’s short-term view and forecast for B8F.DE stock?
Meyka AI’s model gives a 12‑month target of €8.50, implying 24.93% upside from €6.804. The platform flags elevated volatility and the projection is a model estimate, not a guarantee. Monitor fundamentals and regulatory news.
How do Biofrontera’s fundamentals compare within the Healthcare sector for B8F.DE stock?
Biofrontera shows weaker scale: negative EPS -0.21, high price-to-book 21.73, but low EV/EBITDA 3.36. Sector peers typically have larger caps and steadier margins, so Biofrontera carries greater small-cap and execution risk.
Is liquidity adequate to enter or exit a position in B8F.DE stock?
Today’s liquidity surged to 45,797 shares, far above the average 605, creating tradable size intraday. Outside event days liquidity is limited; aim for limit orders and expect larger spreads when volume reverts.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
